Microbix Files First Patent Applications On Novel Technology Platform For Large Semen...

Microbix Files First Patent Applications On Novel Technology Platform For
Large Semen Sexing Market

Company seeks partner to commercialize the technology

TORONTO, July 9 /PRNewswire-FirstCall/ - Microbix Biosystems Inc. (TSX:MBX)
announced today that it has filed key patent applications based on its novel
semen sexing discoveries and that it will now embark on the path to
commercialization of this exciting technology.
Microbix' recent discoveries should provide a more cost-effective platform for
semen sexing and significantly improve yields and quality of the sperm
produced compared to the current commercial sexing technology.
Both are critical market factors that Microbix believes will allow the company
to effectively penetrate and even expand the $3 billion Artificial
Insemination (AI) market.
Semen sexing is instrumental to the dairy industry due to the growing
international demand for female offspring and the negligible value of dairy
bull calves.
"This market is attractive for its size and the absence of regulatory
barriers, and importantly, our technology offers a predictable pathway through
development to market," said William J. Gastle, C.E.O.
"Now that the intellectual property has been secured, we are focused on
finding a strategic partner(s) to help realize Microbix' Semen Sexing
Technology's (SST) significant commercial potential and we invite expressions
of interest," said Mr. Gastle.

Microbix specializes in the development of biological technologies and
commercializing them through global partners. The Company has intellectual
property in large market biotherapeutic drugs, vaccine technologies and animal
reproduction technologies. Established in 1988, Microbix is headquartered in
Mississauga.

This press release contains forward-looking statements, which are subject to
risks and uncertainties that could cause actual results to differ materially
from those set forth in the forward-looking statements including the risks
associated with failure to develop and commercialize SST; non-adoption of SST.
These forward-looking statements represent the Company's judgment as of the
date of this press release. The Company disclaims any intent or obligation to
update these forward-looking statements.

SOURCE Microbix Biosystems Inc.

visit www.microbix.com or contact: Phil Casselli, President, Microbix
Biosystems Inc., (905) 361-8910 x 224; James Long, CFO, Microbix Biosystems
Inc., (416) 234-1624 x 265